Loading…
Loading…
Tenaya Therapeutics NASDAQ: TNYA expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric Hyllengren said during a Canaccord discussion.
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory Discussions on Pivotal Trial Plans for TN-201 and TN-401 Anticipated in 4Q 2026 TN-301 Advancing toward Phase 2 Trial Start in 2H 2027 $10 million Upfront Payment Received from Alnylam Collaboration Extends Cash Runway Through Q3 2027 SOUTH SAN FRANCISCO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of management will host 1x1 meetings with investors at the upcoming Canaccord Genuity 46th Annual Growth Conference taking place from August 11-12, 2026 in Boston, Massachusetts.
SOUTH SAN FRANCISCO, Calif. , July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript